| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615931 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 4 Pages |
Abstract
We suggest routine use of peg-GCSF is an acceptable alternative to daily GCSF, for patients in whom da-EPOCH-R is selected as first-line treatment for aggressive B-NHL.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Mazyar Shadman, Ryan Cassaday, Oliver Press, Andrei Shustov, Ajay Gopal, Stephen D. Smith,